ChemoMetec ASOCSE:CHEMM -1.73%99 Return-on-Tangible-Equity is 37.40% as of Dec. 2025, which is 17% below its 10-year median of 45.20. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr550.54 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 757 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 90.22% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ChemoMetec AS's annualized net income for the quarter that ended in Dec. 2025 was kr188.0 Mil. ChemoMetec AS's average shareholder tangible equity for the quarter that ended in Dec. 2025 was kr502.5 Mil. Therefore, ChemoMetec AS's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 37.40%.
The historical rank and industry rank for ChemoMetec AS's Return-on-Tangible-Equity or its related term are showing as below:
OCSE:CHEMM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 23.04 Med: 45.2 Max: 64.19
Current: 36.13
During the past 13 years, ChemoMetec AS's highest Return-on-Tangible-Equity was 64.19%. The lowest was 23.04%. And the median was 45.20%.
OCSE:CHEMM's Return-on-Tangible-Equity is ranked better than 90.22% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs OCSE:CHEMM: 36.13
ChemoMetec AS (OCSE:CHEMM) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ChemoMetec AS Return-on-Tangible-Equity Related Terms
ChemoMetec AS Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, ChemoMetec AS's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 37.40% mean?
ChemoMetec AS (OCSE:CHEMM) has a Return-on-Tangible-Equity of 37.40% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ChemoMetec AS and its competitors. This is 17% below median its historical median of 45.20. Over the past decade, ChemoMetec AS's Return-on-Tangible-Equity has ranged from 23.04 to 64.19. According to the industry distribution chart, ChemoMetec AS ranks #74 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 9.8%.
Is ChemoMetec AS's Return-on-Tangible-Equity too high?
ChemoMetec AS's current Return-on-Tangible-Equity of 37.40% is 17% below median its 10-year median of 45.20. Over the past 10 years, this metric has ranged from a low of 23.04 to a high of 64.19. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.09. ChemoMetec AS's value of 37.40% is 814.4% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #74 out of 757 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #74 out of 757 companies for Return-on-Tangible-Equity. This places ChemoMetec AS in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.09. ChemoMetec AS's value of 37.40% is 814.4% above this benchmark. Historically, ChemoMetec AS's own Return-on-Tangible-Equity has ranged from 23.04 to 64.19 over the past decade. While the company's 10-year median is 45.20 vs. the industry median of 4.09, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current Return-on-Tangible-Equity of 37.40% is 814.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current Return-on-Tangible-Equity is 37.40%, which is 17% below median its own 10-year median of 45.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr550.54, compared to a current price of kr398.00 — trading 27.7% below its estimated fair value. The current Return-on-Tangible-Equity is 37.40%, which is 17% below median its 10-year median of 45.20 and 814.4% above the Medical Devices & Instruments industry median of 4.09. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Return-on-Tangible-Equity is 37.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr398.00 is trading 27.7% below its estimated GF Value™ of kr550.54.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
Return-on-Tangible-Equity: 37.40% (17% below median its 10-year median of 45.20)
GF Value™: kr550.54 vs. price of kr398.00 (27.7% below fair value)
Industry Position: 814.4% above the Medical Devices & Instruments median (#74 of 757)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score
Get the complete analysis for OCSE:CHEMM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
